New eBook: CAR T-cell Therapy in Hematological Malignancies: Staying Ahead of a Rapidly Evolving Landscape

Get the eBook now to leverage the lessons learned in a decade of innovation and impact the next revolution in cancer immunotherapy
E-book Cover #2

Get Your Free Copy

Download this eBook and leverage the momentum gained from the
62nd ASH Annual Meeting. Stay ahead of the rapidly evolving landscape in
CAR T-cell therapy for hematological malignancies.

The successful development of CD19-targeted chimeric antigen receptor (CAR) T-cell therapies for select B-cell malignancies is one of the most remarkable therapeutic advances in the past decade. In recent years, research in the field of CAR T-cell therapies has intensified. This eBook explores the new targets and approaches that may increase efficacy, decrease toxicity and expand access to these treatments.

In this new eBook we explore:

Group 20
Real world experience with the approved CD19-targeted CAR T-cell therapies
Group 21
CAR T-cell therapies on the horizon for multiple myeloma and progress in the search for CAR T-cell therapies for acute myeloid leukemia
Group 22
Opportunities and challenges of allogeneic CAR T-cells

Receive your free copy today